Dr Geoff Oxnard outlines promising results from the key studies from 2020 on the neoadjuvant or adjuvant treatment of resectable and/or nonmetastatic NSCLC, as well as the value of stereotactic body radiotherapy in place of surgery during the COVID-19 pandemic.